Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement

doi:10.5497/wjp.v4.i1.96

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13715)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-1) series.

Item

Count

PDF

791

WORD

381

HTML

6386

Figures (1-5)

349

Tables (1-1)

502

Sum=8409

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

988

Download

1810

Sum=2798

Publishing Process of This Article

Item

Count

Browse

1152

Download

1356

Sum=2508

Mar 9, 2015 (publication date) through Feb 24, 2025

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Pharmacol. Mar 9, 2015; 4(1): 96-116
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.96

Full Size Figure Download Figure

Figure 1 Hepatocellular carcinoma pathogenetic pathways. Main molecular targets of the major anti-tumoral drugs are indicated. VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptors; TGF-β: Transforming growth factor-β; Erk: Extracellular signal-regulated kinase; EGFR: Epidermal growth factor receptors; PDGFR: Platelet-derived growth factor receptors; TGF-β R: TGF-β receptor; RAS: Rat Sarcoma; RAF: Rapidly accelerated fibrosarcoma; MEK: Mitogen-activated protein kinase kinase; c-Myc: Myelocytomatosis cellular oncogene; PTEN: Phosphatase and tensin homology; PI3K: Phosphoinositide 3-kinase.

Citation: Cuestas ML, Oubiña JR, Mathet VL. Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement. World J Pharmacol 2015; 4(1): 96-116
URL: https://www.wjgnet.com/2220-3192/full/v4/i1/96.htm
DOI: https://dx.doi.org/10.5497/wjp.v4.i1.96